US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
WO2003088903A2
(en)
|
2002-04-17 |
2003-10-30 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
CA2485148A1
(en)
|
2002-05-09 |
2003-11-20 |
Cytokinetics, Inc. |
Pyrimidinone compounds, compositions and methods
|
AU2003252025A1
(en)
|
2002-07-17 |
2004-02-02 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2003262747A1
(en)
*
|
2002-08-21 |
2004-03-11 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2004218080B2
(en)
*
|
2003-03-07 |
2008-01-03 |
Astrazeneca Ab |
Novel fused heterocycles and uses thereof
|
US7687625B2
(en)
*
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7345046B2
(en)
|
2003-05-30 |
2008-03-18 |
Chiron Corporation |
Heteroaryl-fused pyrimidinyl compounds as anticancer agents
|
WO2005018547A2
(en)
*
|
2003-08-15 |
2005-03-03 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
US7939539B2
(en)
|
2003-11-25 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Quinazolinone compounds as anticancer agents
|
AU2005245492A1
(en)
|
2004-05-21 |
2005-12-01 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted quinoline derivatives as mitotic kinesin inhibitors
|
EP1765789B1
(de)
|
2004-06-18 |
2013-02-27 |
Novartis AG |
N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamidderivate und verwandte verbindungen als inhibitoren des kinesinspindelproteins (ksp) zur behandlung von krebs
|
EP1765830B1
(de)
|
2004-07-01 |
2010-09-22 |
Merck Sharp & Dohme Corp. |
Inhibitoren von mitotischem kinesin
|
JP2008509977A
(ja)
|
2004-08-18 |
2008-04-03 |
アストラゼネカ アクチボラグ |
癌の処置及び予防における選択された縮合複素環の鏡像異性体及びその使用
|
RU2007118523A
(ru)
|
2004-10-19 |
2008-11-27 |
Новартис Вэксинс Энд Диагностикс Инк. (Us) |
Производные индола и бензимидазола
|
AU2006206738A1
(en)
*
|
2005-01-19 |
2006-07-27 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
US7608643B2
(en)
|
2005-03-09 |
2009-10-27 |
Schering Corporation |
Compounds for inhibiting KSP kinesin activity
|
PE20061484A1
(es)
*
|
2005-03-09 |
2007-02-05 |
Schering Corp |
Compuestos triciclicos fusionados como inhibidores de la actividad de quinesina de ksp
|
JP2008533019A
(ja)
*
|
2005-03-09 |
2008-08-21 |
シェーリング コーポレイション |
Kspキネシン活性を阻害するための化合物
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US20070099941A1
(en)
*
|
2005-11-02 |
2007-05-03 |
Cytovia, Inc. |
N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
WO2007056214A2
(en)
*
|
2005-11-02 |
2007-05-18 |
Cytovia, Inc |
N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
|
US20070099877A1
(en)
*
|
2005-11-02 |
2007-05-03 |
Cytovia, Inc. |
N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US7538114B2
(en)
*
|
2006-06-28 |
2009-05-26 |
Amgen Inc. |
Glycine transporter-1 inhibitors
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2097422A4
(de)
*
|
2006-11-13 |
2010-04-14 |
Lilly Co Eli |
Thienopyrimidinone zur behandlung von entzündungserkrankungen und karzinomen
|
US8129358B2
(en)
|
2006-11-13 |
2012-03-06 |
Novartis Ag |
Substituted pyrazole and triazole compounds as KSP inhibitors
|
BRPI0806264A2
(pt)
|
2007-01-05 |
2011-08-30 |
Novartis Ag |
derivados ciclizados como inibidores de eg-5
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EP2413932A4
(de)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
Hemmer der akt-aktivität
|
CA2766100C
(en)
|
2009-06-29 |
2018-05-22 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
JP2013500257A
(ja)
|
2009-07-21 |
2013-01-07 |
ギリアード カリストガ エルエルシー |
Pi3kインヒビターでの肝障害の処置
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
EP2558463A1
(de)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Kondensierte derivate als i3-hemmer
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
EP2455456A1
(de)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
IL299533A
(en)
|
2011-09-02 |
2023-02-01 |
Incyte Holdings Corp |
Heterocycloamines as P13K inhibitors
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
HUE060953T2
(hu)
|
2015-02-27 |
2023-04-28 |
Incyte Holdings Corp |
Eljárások PI3K inhibitor elõállítására
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
SG11201804901WA
(en)
|
2015-12-22 |
2018-07-30 |
SHY Therapeutics LLC |
Compounds for the treatment of cancer and inflammatory disease
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
JP7160833B2
(ja)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
抗sirpアルファ抗体
|
EA201992780A1
(ru)
|
2017-06-21 |
2020-06-02 |
ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи |
Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
US20230108452A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
US11932656B1
(en)
|
2023-10-06 |
2024-03-19 |
King Faisal University |
Thieno[2,3-d]pyrimidines as COX-2 inhibitors
|